Buprenorphine
FDA-approved product (film, extended release, transdermal), marketed as Brixadi, Buprenorphine, Butrans and 6 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic pain
- Drug dependence
- Opioid dependence
- Opioid use disorder
- Overdose
- Pain
- Substance abuse
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Oripavine derivatives; Drugs used in opioid dependence
- FDA pharmacologic class
- Partial Opioid Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not docked: the structure could not be prepared for dockingdetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not docked: the structure could not be prepared for dockingdetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not docked: the structure could not be prepared for dockingdetails
Dihydrofolate reductase ↗ (MRSA)
Not docked: the structure could not be prepared for dockingdetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Buprenorphine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2
NCT00015041 · start 1996-11
Registered record
- Registry ID
- NCT00015041
- Conditions
- Opioid-Related Disorders; Substance-Related Disorders
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1996-11
- Completion
- 1998-07
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid-Related Disorders; Substance-Related DisordersInterventionBuprenorphinePhasePhase 1Registry statusCompletedAlternate-Day Buprenorphine Administration. Phase II - 4
NCT00000222 · start 1992-07
Registered record
- Registry ID
- NCT00000222
- Conditions
- Opioid-Related Disorders
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1992-07
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid-Related DisordersInterventionBuprenorphinePhasePhase 1Registry statusCompletedAlternate-Day Buprenorphine Administration. Phase I - 3
NCT00000221 · start 1992-04
Registered record
- Registry ID
- NCT00000221
- Conditions
- Opioid-Related Disorders
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1992-04
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid-Related DisordersInterventionBuprenorphinePhasePhase 1Registry statusCompletedBuprenorphine Maintenance for Opioid Addicts - 2
NCT00000203 · start 1988-08
Registered record
- Registry ID
- NCT00000203
- Conditions
- Opioid-Related Disorders
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1988-08
- Completion
- 2006-05
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid-Related DisordersInterventionBuprenorphinePhasePhase 2Registry statusCompletedStudy Comparing Liquid and Tablet Buprenorphine Formulations - 5
NCT00000302
Registered record
- Registry ID
- NCT00000302
- Conditions
- Heroin Dependence
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeroin DependenceInterventionBuprenorphinePhasePhase 3Registry statusCompleted